Ian Wilkinson, Chief Scientific Officer at mAbsolve, has an outstanding scientific background in the engineering and development of therapeutic antibodies. During a UCB-Celltech sponsored PhD at the University of Leicester, Dr. Wilkinson solved the first NMR structure of a single-chain variable fragment. He subsequently moved to MedImmune, the biologics arm of AstraZeneca, where he worked on a number of antibody and non-antibody early-stage therapeutic research projects covering technology validation, drug discovery and optimization. In 2012 he joined the new start-up Absolute Antibody as CSO and built the company up from the ground to an established CRO offering a suite of recombinant antibody services and products to biopharmaceutical and academic clients worldwide. Following the acquisition of Absolute Antibody, he stepped down as CSO but remains an advisor to the company. Dr. Wilkinson’s insights into antibody structure and engineering led to the invention of mAbsolve’s lead STR technology for elimination of the binding of antibodies to Fc-gamma receptors. [1] He has been heavily involved in the development of the technology and is now actively engaged in commercializing it.
- Wilkinson I, Anderson S, Fry J, Julien LA, Neville D, Qureshi O, Watts G, Hale Fc-engineered antibodies with immune effector functions completely abolished. G.PLoS One. 2021 Dec 21;16(12):e0260954. doi: 10.1371/journal.pone.0260954.
